Toa Eiyo Ltd.

Yamasa Corporation

Kazuhiro Uemoto

Yoshikazu Kato

Masayuki Kageyama

Takashi Konno

Yoshimichi Sato

Naoki Okada

Emiko Iimori

Shinya Onuma

Shin-ichi Kazayama

Koichi Takayanagi

Shin-Ichi Kazayama

A compound represented by general formula (1) a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C-Calkyl group; A represents a C-Calkylene chain which may be substituted with two C-Calkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below: 

4-aminomethylbenzoic acid derivative

Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C-Clinear alkylene group, in which one methylene group is optionally substituted with O or S;n represents an integer of from 3 to 5;Xand Xeach independently represent CH or N;Wand Weach independently represent a carboxyl group or a tetrazolyl group;V represents a C-Clinear or branched alkylene group, in which one methylene group is optionally substituted with O or S; andR represents a substituted phenyl group, for example.

Bicyclic compound

The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na/Hexchanger (NHE). There is provided a cyclohepta[b]pyridine-3-carbonylguanidine derivative represented by Formula (1): wherein Ris a group selected from a sulfo group, a sulfoxy group, &#x2014;OCONH&#x2014;(CHCHO)&#x2014;SOH and the following formulas: Rrepresents a halogen atom, a lower alkyl group or a lower alkoxy group; and n represents an integer from 1 to 10,

Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same

2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5'-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.

Adenosine derivatives and use thereof

Growing community of inventors

Saitama, Japan

Kazuhiro Uemoto